Eloxx Pharmaceuticals, Inc. (ELOX) Stock

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.

Eloxx Pharmaceuticals, Inc. (ELOX) stock trades at $10.78 with a market capitalization of $81.64M. The stock is valued at a price-to-earnings (P/E) ratio of -2.05, price-to-book of -6.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.20 and $17.50, and currently trades 38.4% below its 52-week high.

On profitability, Eloxx Pharmaceuticals, Inc. generates a return on equity (ROE) of 72.03% — well above the market average, a sign of a high-quality business, return on capital employed of 66.15%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.eloxxpharma.com